Blood type as a risk factor for pancreatic ductal adenocarcinoma.
Rahimi Larki N, Skanderson M, Tate J, Levinson R, Hauser R, Brandt C, Yang Y, Justice A, Wang L. Blood type as a risk factor for pancreatic ductal adenocarcinoma. Journal Of Clinical Oncology 2024, 42: 10559-10559. DOI: 10.1200/jco.2024.42.16_suppl.10559.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinoma riskVeterans Health AdministrationRisk of pancreatic ductal adenocarcinomaNon-O blood typeNeighborhood-level socioeconomic dataIntegrated healthcare systemHigh risk of pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaAssociated with higher riskAssociated with increased riskUnited StatesHealth AdministrationOutpatient encountersHealthcare systemBaseline ageAlcohol useIndex dateAssociation of blood typeCancer deathWhite populationSocioeconomic dataBlack patientsDiverse populationsRisk factorsBlood typeDecreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource
Ito S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024, 99: 570-576. PMID: 38279581, DOI: 10.1002/ajh.27211.Peer-Reviewed Original ResearchSickle cell diseaseDelayed hemolytic transfusion reactionQuality-adjusted life expectancyAlloimmunized patientsPatient populationRed blood cell alloimmunizationCell diseaseCost-effective interventionMedical expenditure of patientsHealth system perspectiveExpenditure of patientsIncremental cost-effectiveness ratioHemolytic transfusion reactionsUnited StatesMarkov cohort simulationCost-effectiveAverage patient populationCost-effectiveness ratioBirth cohortAnalytical time horizonAntibody historyCohort simulationTransfusionTransfusion reactionsLife expectancy